RecruitingNCT05363657
International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Principal Investigator
- Andrea Minervini, Prof.Dipartimento di Medicina Clinica e Sperimentale Via o Piazza Largo Brambilla 3 - 50134 Firenze (Italy)
- Intervention
- Partial Nephrectomy (PN)(procedure)
- Enrollment
- 10000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (30)
- Institute of Urology, University of Southern California., Los Angeles, California, United States
- University of California San Diego, Moores Cancer Center, San Diego, California, United States
- Stanford University, Stanford, California, United States
- Loyola University Medical Center, Edward Hines VA Hospital, Chicago, Illinois, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- VCU Health System, Richmond, Virginia, United States
- Swedish Hospital, Seattle, Washington, United States
- Medical University of Vienna, Vienna General Hospital, Vienna, Austria
- University of Bruxelles, Brussels, Belgium
- University Hospitals Leuven, Leuven, Belgium
- Onze Lieve Vrouw Hospital, Leuven, Belgium
- Santa Casa da Misericórdia de Fortaleza, Fortaleza, Brazil
- University of Patras, Pátrai, Greece
- Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy
- Policlinico S. Orsola Malpighi, Bologna, Italy
- +15 more locations on ClinicalTrials.gov
Collaborators
Società Italiana di Urologia (SIU) · Italian Group for Advanced Laparo-Endoscopic and Robotic Urologic Surgery (AGILE)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05363657 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →